Cargando…
T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
Over the last decades, T-cell immunotherapy has revealed itself as a powerful, and often curative, strategy to treat blood cancers. In hematopoietic cell transplantation, most of the so-called graft-vs.-leukemia (GVL) effect hinges on the recognition of histocompatibility antigens that reflect immun...
Autores principales: | Janelle, Valérie, Rulleau, Caroline, Del Testa, Simon, Carli, Cédric, Delisle, Jean-Sébastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046834/ https://www.ncbi.nlm.nih.gov/pubmed/32153583 http://dx.doi.org/10.3389/fimmu.2020.00276 |
Ejemplares similares
-
Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture
por: Janelle, Valérie, et al.
Publicado: (2015) -
Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019) -
T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies
por: Janelle, Valérie, et al.
Publicado: (2021) -
Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies
por: Mancini, Stéphane J.C., et al.
Publicado: (2021) -
Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8(+) antigen-specific T cells for adoptive immunotherapy
por: Lak, Shirin, et al.
Publicado: (2022)